Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]